Id |
Subject |
Object |
Predicate |
Lexical cue |
TextSentencer_T1 |
0-79 |
Sentence |
denotes |
DNA methylation and histone H3-K9 modifications contribute to MUC17 expression. |
T1 |
0-79 |
Sentence |
denotes |
DNA methylation and histone H3-K9 modifications contribute to MUC17 expression. |
T1 |
0-79 |
Sentence |
denotes |
DNA methylation and histone H3-K9 modifications contribute to MUC17 expression. |
TextSentencer_T2 |
80-178 |
Sentence |
denotes |
MUC17 glycoprotein is a membrane-associated mucin that is mainly expressed in the digestive tract. |
T2 |
80-178 |
Sentence |
denotes |
MUC17 glycoprotein is a membrane-associated mucin that is mainly expressed in the digestive tract. |
T2 |
80-178 |
Sentence |
denotes |
MUC17 glycoprotein is a membrane-associated mucin that is mainly expressed in the digestive tract. |
TextSentencer_T3 |
179-312 |
Sentence |
denotes |
It has been suggested that MUC17 expression is correlated with the malignancy potential of pancreatic ductal adenocarcinomas (PDACs). |
T3 |
179-312 |
Sentence |
denotes |
It has been suggested that MUC17 expression is correlated with the malignancy potential of pancreatic ductal adenocarcinomas (PDACs). |
T3 |
179-312 |
Sentence |
denotes |
It has been suggested that MUC17 expression is correlated with the malignancy potential of pancreatic ductal adenocarcinomas (PDACs). |
TextSentencer_T4 |
313-506 |
Sentence |
denotes |
In the present study, we provided the first report of the MUC17 gene expression through epigenetic regulation such as promoter methylation, histone modification and microRNA (miRNA) expression. |
T4 |
313-506 |
Sentence |
denotes |
In the present study, we provided the first report of the MUC17 gene expression through epigenetic regulation such as promoter methylation, histone modification and microRNA (miRNA) expression. |
T4 |
313-506 |
Sentence |
denotes |
In the present study, we provided the first report of the MUC17 gene expression through epigenetic regulation such as promoter methylation, histone modification and microRNA (miRNA) expression. |
TextSentencer_T5 |
507-688 |
Sentence |
denotes |
Near the transcriptional start site, the DNA methylation level of MUC17-negative cancer cell lines (e.g. PANC1) was high, whereas that of MUC17-positive cells (e.g. AsPC-1) was low. |
T5 |
507-688 |
Sentence |
denotes |
Near the transcriptional start site, the DNA methylation level of MUC17-negative cancer cell lines (e.g. PANC1) was high, whereas that of MUC17-positive cells (e.g. AsPC-1) was low. |
T5 |
507-688 |
Sentence |
denotes |
Near the transcriptional start site, the DNA methylation level of MUC17-negative cancer cell lines (e.g. PANC1) was high, whereas that of MUC17-positive cells (e.g. AsPC-1) was low. |
TextSentencer_T6 |
689-776 |
Sentence |
denotes |
Histone H3-K9 (H3-K9) modification status was also closely related to MUC17 expression. |
T6 |
689-776 |
Sentence |
denotes |
Histone H3-K9 (H3-K9) modification status was also closely related to MUC17 expression. |
T6 |
689-776 |
Sentence |
denotes |
Histone H3-K9 (H3-K9) modification status was also closely related to MUC17 expression. |
TextSentencer_T7 |
777-917 |
Sentence |
denotes |
Our results indicate that DNA methylation and histone H3-K9 modification in the 5' flanking region play a critical role in MUC17 expression. |
T7 |
777-917 |
Sentence |
denotes |
Our results indicate that DNA methylation and histone H3-K9 modification in the 5' flanking region play a critical role in MUC17 expression. |
T7 |
777-917 |
Sentence |
denotes |
Our results indicate that DNA methylation and histone H3-K9 modification in the 5' flanking region play a critical role in MUC17 expression. |
TextSentencer_T8 |
918-993 |
Sentence |
denotes |
Furthermore, the hypomethylation status was observed in patients with PDAC. |
T8 |
918-993 |
Sentence |
denotes |
Furthermore, the hypomethylation status was observed in patients with PDAC. |
T8 |
918-993 |
Sentence |
denotes |
Furthermore, the hypomethylation status was observed in patients with PDAC. |
TextSentencer_T9 |
994-1124 |
Sentence |
denotes |
This indicates that the hypomethylation status in the MUC17 promoter could be a novel epigenetic marker for the diagnosis of PDAC. |
T9 |
994-1124 |
Sentence |
denotes |
This indicates that the hypomethylation status in the MUC17 promoter could be a novel epigenetic marker for the diagnosis of PDAC. |
T9 |
994-1124 |
Sentence |
denotes |
This indicates that the hypomethylation status in the MUC17 promoter could be a novel epigenetic marker for the diagnosis of PDAC. |
TextSentencer_T10 |
1125-1230 |
Sentence |
denotes |
In addition, the result of miRNA microarray analysis showed that five potential miRNA candidates existed. |
T10 |
1125-1230 |
Sentence |
denotes |
In addition, the result of miRNA microarray analysis showed that five potential miRNA candidates existed. |
T10 |
1125-1230 |
Sentence |
denotes |
In addition, the result of miRNA microarray analysis showed that five potential miRNA candidates existed. |
TextSentencer_T11 |
1231-1369 |
Sentence |
denotes |
It is also possible that the MUC17 might be post-transcriptionally regulated by miRNA targeting to the 3'-untranslated region of its mRNA. |
T11 |
1231-1369 |
Sentence |
denotes |
It is also possible that the MUC17 might be post-transcriptionally regulated by miRNA targeting to the 3'-untranslated region of its mRNA. |
T11 |
1231-1369 |
Sentence |
denotes |
It is also possible that the MUC17 might be post-transcriptionally regulated by miRNA targeting to the 3'-untranslated region of its mRNA. |
TextSentencer_T12 |
1370-1537 |
Sentence |
denotes |
These understandings of the epigenetic changes of MUC17 may be of importance for the diagnosis of carcinogenic risk and the prediction of outcomes for cancer patients. |
T12 |
1370-1537 |
Sentence |
denotes |
These understandings of the epigenetic changes of MUC17 may be of importance for the diagnosis of carcinogenic risk and the prediction of outcomes for cancer patients. |
T12 |
1370-1537 |
Sentence |
denotes |
These understandings of the epigenetic changes of MUC17 may be of importance for the diagnosis of carcinogenic risk and the prediction of outcomes for cancer patients. |